Home » Newsletters » BioWorld Science

BioWorld Science

Sep. 1, 2010

View Archived Issues

Pharmasset selects anti-HCV purine nucleotide prodrugs to develop

Yissum claims new MMP-2 inhibitors

Early control of blood pressure achieved by telmisartan/nifedipine GIST, TALENT data suggest

MyD88 inhibitor STJJ induces tolerance of skin transplants in mice

Metformin has beneficial effects in patients with chronic heart failure

Phase II and III trials examine SIR-Spheres in patients with refractory colorectal liver metastases

STX-100 receives FDA orphan drug designation for IPF

Glenmark discovers novel TRPA1 receptor antagonist GRC-17536

FDA grants orphan drug designation to BMN-701 for Pompe's disease

New GHS-R antagonists claimed by sanofi-aventis

Celgene discovers new isotopologues of lenalidomide

New GlyT-1 inhibitors identified by sanofi-aventis

Janssen presents novel antibacterial agents

BTG to receive marketing rights for Nycomed's CroFab and DigiFab

Health Canada approves Sativex for spasticity due to MS

FDA approves Suboxone sublingual film

Meda to acquire specialty pharmaceutical company, Alaven

Pluristem's PLX cells included in diastolic heart failure program

Treatment with MP4OX effective in severe trauma patients

Positive outcome to decentralized procedure for European approval of Twinject

PEARL-HF study shows reduced hyperkalemia with RLY-5016

FDA approves Lumigan 0.01% for reducing IOP in glaucoma patients

ImmuneRegen to submit proposal for funding Homspera development

Otonomy closes Series B financing

Neurotech initiates phase I AAD-2004 trial targeting AD, PD and ALS

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 30, 2025.
Today's news in brief
Briefs
BioWorld MedTech briefs for Jan. 30, 2026.
Brain-derived tau in blood predicts stroke severity and outcome
BioWorld Science
Brain-derived tau, a protein that is exclusive to the brain and detectable in the blood, could serve as an indicator of brain damage after an ischemic stroke. The...
Centessa’s CNT-9982 shows promise for MDD
BioWorld Science
Orexin OX2 receptor agonists have demonstrated the ability to enhance wakefulness in rodent models, as well as in nonhuman primates and patients with narcolepsy...
First-in-class ADC targeting DEM-TXX shows high preclinical efficacy
BioWorld Science
Researchers at DEM Biopharma Inc. reported preclinical findings demonstrating the efficacy of DEM-301, a bifunctional antibody-drug conjugate (ADC) engineered to...